CapEdge
Loading...
Advanced
What's new? Log in Free sign up
  • Home
  • Sectors & IndustriesSectors
  • Earnings
  • IPOs
  • SPACs
  • Transcripts
  • Insider
  • Institutional
  • Crypto
  • Screeners
  • Reddit
  • Splits
  • KMDA Dashboard
  • Financials
  • Filings
  • Transcripts
  • ETFs
  • Institutional
  • Shorts
  • News
  • Patents
  • Reddit
  • 6-K Filing

Kamada (KMDA) 6-KReport of Foreign Private Issuer

Filed: 22 Nov 21, 7:02am
Free signup for more
  • Track your favorite companies
  • Receive email alerts for new filings
  • Personalized dashboard of news and more
  • Access all data and search results
Sign up for free
Search this filing
?
Pre-defined:
Table of contents
    Filing tables
    Export all tables to Excel
    Filing exhibits
    SEC
    • 6-K Current report (foreign)
    • 99.1 Kamada' Press Release, Dated November 22, 2021, Titled "Kamada Reports Third Quarter and First Nine Months of 2021 Financial Results, and Strategic Transformational Acquisition"
    • 99.2 Kamada LTD.'S Consolidated Financial Statements As of September 30, 2021 (Unaudited)
    • Download Excel data file
    • View Excel data file
    KMDA similar filings
    • 2 Mar 22 Report of Foreign Private Issuer
    • 16 Dec 21 Report of Foreign Private Issuer
    • 22 Nov 21 Report of Foreign Private Issuer
    • 22 Nov 21 Report of Foreign Private Issuer
    • 8 Nov 21 Report of Foreign Private Issuer
    • 4 Nov 21 Report of Foreign Private Issuer
    • 11 Aug 21 Kamada Reports Second Quarter and First Half 2021 Financial Results, Recent Achievements and Corporate Development Activities
    Filing view
    Share this filing

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    FORM 6-K

     

    Report of Foreign Private Issuer

    Pursuant to Rule 13a-16 or 15d-16

    of the Securities Exchange Act of 1934

     

    For the Month of November 2021

     

    Commission File Number 001-35948

     

    Kamada Ltd.

    (Translation of registrant’s name into English)

     

    2 Holzman Street
    Science Park, P.O. Box 4081
    Rehovot 7670402
    Israel
    (Address of principal executive offices)

     

    Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.

     

    Form 20-F ☒ Form 40-F ☐

     

    Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ____

     

    Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ____

     

    Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

     

    Yes ☐ No ☒

     

    If “Yes” is marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b): 82-____

     

    This Form 6-K is being incorporated by reference into the Registrant’s Form S-8 Registration Statements, File Nos. 333-192720, 333-207933, 333-215983, 333-222891 and 333-233267, and the Registrant’s Form F-3 Registration Statement, as amended, File No. 333-214816.

     

     

     

     

     

     

    The following exhibits are attached:

     

    99.1 Kamada’ press release, dated November 22, 2021, titled “Kamada Reports Third Quarter and First Nine Months of 2021 Financial Results, and Strategic Transformational Acquisition of a Portfolio of Four FDA-Approved Plasma-Derived Hyperimmune Commercial Products”
       
    99.2 Kamada Ltd.’s Consolidated Financial Statements as of September 30, 2021 (Unaudited)

     

    1

     

     

    SIGNATURE

     

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     

    Date: November 22, 2021

    KAMADA LTD.

                        
     By:/s/ Yifat Philip
     

     

    Yifat Philip

    Vice President General Counsel and
    Corporate Secretary

     

    2

     

     

    EXHIBIT INDEX

     

    EXHIBIT NO. DESCRIPTION
       
    99.1 Kamada’ press release, dated November 22, 2021, titled “Kamada Reports Third Quarter and First Nine Months of 2021 Financial Results, and Strategic Transformational Acquisition of a Portfolio of Four FDA-Approved Plasma-Derived Hyperimmune Commercial Products”
       
    99.2 Kamada Ltd.’s Consolidated Financial Statements as of September 30, 2021 (Unaudited)

     

     

    3

     

     

    Finsight
    Resources
    • Knowledgebase
    • Log In
    • Register
    Company
    • About
    • Contact
    • Solutions
    Products
    • Deal Roadshow
    • DealVDR
    • Evercall
    • Finsight.com
    CapEdge
    • Earnings Calendar
    • Earnings Transcripts
    • EDGAR Filing Screener
    • IPO Calendar
    • Compliance
    • Privacy
    • Security
    • Terms
    AngelList LinkedIn